Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Jul 13;103(3):332–339. doi: 10.1038/sj.bjc.6605767

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2010 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Efficacy of figitumumab and docetaxel in patients with CRPC. (A) Waterfall plot of maximal CTC declines in individual patients with baseline CTC count of ⩾5 per 7.5 ml, treated with figitumumab and docetaxel. Dotted lines indicate CTC declines of 30, 50, and 90%, respectively. (B) Radiologic response in a patient with metastatic disease to bilateral pelvic nodes. This patient also had extensive retroperitoneal (not shown) and bony metastases with a baseline PSA of 11 291 μg l^–1. Bilateral pelvic nodal metastatic deposits are indicated by circles at baseline (pre-treatment image). After four cycles of therapy, nodal disease showed a significant reduction in size (post-treatment image); PSA fell to a nadir of 1578 μg l^–1. The patient completed eight cycles of treatment with a maintained radiologic response, but with PSA progression and docetaxel-related fatigue. (C) Waterfall plot of PSA change from baseline to 12 weeks. (D) Waterfall plot of maximal PSA change for individual patients. Dotted lines indicate PSA declines of 30, 50, and 90%. Some patients had a PSA decline on study but this was short lived and PSA then rose again, explaining why the week 12 and maximal PSA declines are different. Abbreviations: CRPC, castration-resistant prostate cancer; CTC, circulating tumour cells; PSA, prostatic-specific antigen.